In this episode, we mainly watch the live MAPS press conference that I was invited to, where leadership addressed the FDA’s newly released complete response letter rejecting MDMA assisted therapy for PTSD. You’ll hear their perspective on shifting standards, trial design disputes, and what this decision means for the future of psychedelic medicine. To set the stage, I begin with a clip from Hamilton Morris on drug journalism and the FDA’s rejection of MDMA therapy, then we tune into the full press conference. Links to the FDA letter, my article covering the decision, and outside analysis are included in the show notes. Watch video version and read full show notes here: https://thecolememo.com/2025/09/05/maps-fda/